fashion -WSS

fashion

author：comprehensive 2025-09-27 23:32:49 - browse：9839

Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs well with a biotech downturn?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Casey Ross joins us to tell the bombshell story of how the nation’s largest health insurer used a computer algorithm to deny patient care and boost its profitability. Then, biotech veteran Michael Gilman calls in to offer a behind-the-scenes peek at what it’s like to be a startup CEO in this economic downturn — and which cocktail recipes help make it bearable. We also discuss a pioneering approval for a genome-editing medicine.

For more on what we cover, here’s the UnitedHealth story; here’s more on the CRISPR approval; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： The Readout: Gilead, Bernie Sanders, and other pharma news

hotspot

WSS

How digital tools helped lower hypertension in marginalized patients

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Industry veterans launch new biotech VC with $310M

BioAge raises $170M for combination therapy with Zepbound

After gene therapy, two congenitally deaf children hear for the first time

What we’ve learned from the Aduhelm mess

hotspot

fashion

Wikipedia

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

H5N1 bird flu: what we're starting to learn about infection in cows

Jerome Adams on the need for new antivirals for Covid

Software glitch causes Tandem insulin pump to shutdown, FDA warns

BioMarin wins approval for gene therapy to treat hemophilia A

Study: Adult vaccinations pay for themselves in societal benefits

The cancer drug shortage isn’t new — and neither are the solutions

For Medicare Advantage, Democrats want stronger protections around AI

Walensky prepares to leave CDC — and Congress — behind

Researchers on aging grapple with how to calculate biological age

leisure time

Elevance, private equity launch primary care company

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Key House Republican on health care plans exit from Congress

Study: AI not yet building 'n

Industry veterans launch new biotech VC with $310M

For Medicare Advantage, Democrats want stronger protections around AI

hotspot

leisure time

explore

Wikipedia